Rigel Pharmaceuticals (RIGL) Gains from Investment Securities (2010 - 2025)

Rigel Pharmaceuticals' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $1.4 million for Q3 2025.

• In Q3 2025, Gains from Investment Securities fell 7.39% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.3 million (down 34.88% YoY), while the FY2025 annual figure was $1.1 million, up 48.23% from the prior year.
• Gains from Investment Securities was $1.4 million for Q3 2025 at Rigel Pharmaceuticals, up from $1.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.1 million in Q3 2023 to a low of -$510000.0 in Q1 2022.
• Historically, Gains from Investment Securities has averaged $4.5 million across 5 years, with a median of $1.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities sank 8400.0% in 2022, then surged 7374.65% in 2024.
• A 5-year view of Gains from Investment Securities shows it stood at $39000.0 in 2021, then soared by 1669.23% to $690000.0 in 2022, then plunged by 75.94% to $166000.0 in 2023, then surged by 331.99% to $717106.0 in 2024, then soared by 96.34% to $1.4 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.2 million (Q1 2025), per Business Quant data.